Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies: the GHSG experience
Mené sur 45 patients atteints d'un lymphome hodgkinien CD30+ réfractaire ou récidivant, cet essai allemand évalue, du point de vue du taux de réponse objective, le brentuximab vedotin en monothérapie
The CD30 targeting antibody-drug conjugate brentuximab vedotin (SGN-35) was recently approved for the treatment of relapsed Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) by the Food and Drug Administration (FDA). Here, we report the experience of the German Hodgkin Study Group (GHSG) with brentuximab vedotin as single agent in 45 patients with refractory or relapsed CD30-positive HL who were treated either in a named patient program (n=34) or in the context of a safety study associated with the registration program of this drug. In these very heavily pre-treated patients, an objective response rate of 60% including 22% complete remissions could be documented. The median duration of response was 8 months. This retrospective analysis supports the previously reported excellent therapeutic efficacy of brentuximab vedotin in heavily pre-treated CD30-positive malignancies. This trial was registered at www.ClinicalTrials.gov with identifier NCT01026233.